Magnesium: Pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage, 2019
Georgetown University School of Medicine, Washington, DC, USA
University of Tennessee Health Science Center, Memphis, TN, USA

“...Conclusion

The physiological properties of magnesium in ICH are not as well understood as with ischemic stroke models. However, three key properties of magnesium—vasodilation, hemostasis, and reduction of PHE through BBB preservation—may make magnesium therapy a worthwhile future target for improving clinical outcome after ICH. Although two large randomized trials did not demonstrate efficacy of magnesium therapy in ICH, both trials were not designed to optimize therapeutic targets for ICH pathophysiology. In contrast, several recent large retrospective trials have demonstrated associations in ICH between low admission serum magnesium levels and clinical outcome, admission hematoma volume, and hematoma expansion. The results of these studies [Table 1] suggest that with a proper methodology focused on ICH pathophysiology, magnesium may prove to have some clinical benefit in ICH[55]...”

Full paper: http://www.nrronline.org/article.asp?issn=1673-5374;year=2019;volume=14;issue=7;spage=1116;epage=1121;aulast=Chang

Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,China